35 results about "Substance addiction" patented technology

A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.

Systems and methods for treatment for addiction to a substance according to a predetermined action plan that includes a message control center for sending information to a messaging-accessible device associated with a user, an analyzer for analyzing an indicia of use of said substance, and a personalized treatment engine to receive an output from the analyzer and to direct the message control center based, at least in part, on the output from the analyzer and the predetermined action plan for the user.

A pharmaceutical composition includes a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-S-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-S-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.

The invention relates to methods of administering pharmaceutical compositions and dosage forms comprising the sertindole derivatives nor-sertindole, 5-oxo-sertindole, dehydro-sertindole, and dehydro-nor-sertindol. The methods of the invention are directed to the treatment and prevention of neuroleptic and related disorders such as, psychotic disorders, depression, anxiety, substance addiction, memory impairment and pain.

Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), Tourette's Syndrome, and neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder).

The present invention provides a highly efficient method for treating substance addiction and for changing addiction-related behavior of a mammal suffering from substance addiction. The method includes administering to a mammal an effective amount of gamma vinylGABA or a pharmaceutically acceptable salt thereof. The present invention also provides a method of treatment of cocaine, morphine, heroin, nicotine, amphetamine, methamphetamine, or ethanol addiction by treating a mammal with an effective amount of gamma vinylGABA or a pharmaceutically acceptable salt thereof.

This invention relates to compositions containing combinations of a balanced PC composition and one or more cannabinoids, a natural or synthetic derivative thereof, or a salt thereof, and kits containing such combinations and methods of using such combinations to treat subjects suffering from addiction to substances and related diseases or disorders. This invention also relates to the synergistic effect of such combination therapies in humans.

The invention pertains to systems and methods for preventing or reducing the probability of human addiction to various substances and / or treating those currently or previously addicted to substances. The invention includes a sensing mechanism to detect a presence of the addictive substance or a condition resulting from the presence of the addictive substance, a signaling mechanism to generate a signal as a result of the sensing mechanism detecting the presence of the addictive substance or a condition resulting from the presence of the addictive substance, and a receiving mechanism to provide at least one response as a result of receiving as input the signal generated by the signaling mechanism

The present invention provides a highly efficient method for treating substance addiction and for changing addiction-related behavior of a primate suffering from substance addiction. The method includes administering to a primate an effective amount of a pharmaceutical composition including gamma vinylGABA. The present invention also provides a method of treatment of nicotine addiction by treating a patient with an effective amount of a composition including gamma vinylGABA.

The invention relates to an application of a lead compound namely L-corydalmine (L-CDL) of isoquinoline compounds on treating diseases related with addiction. The diseases comprise drug addiction (heroin, opium, methyl amphetamine, morphine, marihuana, cocaine, and the like), nicotine addiction, and alcohol addiction, and also comprise novel drug addiction (stimulant type novel drugs) and brain damage caused by novel drugs.

Disclosed herein are compounds of formula (I); as defined herein, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same, and methods of using these compounds for the treatment of substance addiction.

A pharmaceutical composition to be administered to mammals via the mucosal route consisting of a vehicle system comprising mono- / dietherglycerides conjugated with a water soluble polymer groups selected from PEG's containing 2-30 polyoxyethylene units, an antigen and optionally a bacterial toxin for the augmentation of immune responses for vaccination, immunisation, treatment of allergy, treatment of cancer, treatment of infectious disease, treatment of an autoimmune disease, Alzheimer's, substance addiction or the treatment of a disease which is fully or partially controlled by the body immune system.

The present invention provides methods for treating a substance addiction- related behavior in a patient with a substance addiction, comprising the step of locally administering a therapeutically effective amount of a botulinum neurotoxin to a location on the patient's body or in the vicinity of the area which comes into contact with a smoking tool or addictive substance, thereby altering, reducing or eliminating sensations associated with behaviors associated with substance addiction. Botulinum neurotoxin may be administered to a dermal, subdermal, mucosal or submucosal location or to a muscle area or in the vicinity of the location to which a smoking tool or addictive substance contacts.

The present invention relates to methods of therapy for substance addiction comprising the administration to a subject in need thereof a combination of: (i) a mu-opioid receptor antagonist; (ii) a calcium channel blocker which is long-acting or in sustained-release form or which is nimodipine in rapid release form; and (iii) an NMDA glutamate receptor modulator; as well as combinations, kits and composition useful therefor.

The invention discloses an application of mTOR (mammalian Target of Rapamycin) serving as a target to screening of a medicament for treating nicotine addiction. The mTOR is taken as a target for preparing a medicament for treating nicotine substance addiction. An effective medicament acting target is provided for the treatment of symptoms such as nicotine substance addiction and excitability, and can be used for radically treating nicotine substance addiction.

The invention relates to a drug containing a heterocyclic system of a hexatomic ring with nitrogen as a heteroatom, in particular to an application of hirsutine in preparing a drug for preventing and treating opioid substance addiction or amphetamine substance dependence. The drug is composed of the hirsutine and a pharmaceutically acceptable auxiliary material, wherein, the hirsutine content is 5-85%. The drug is oral preparation such as a tablet or a capsule and the like.

The invention relates to compounds having the general formula (I) wherein R1 is phenyl, R2 is meta-substituted phenyl; rTA is a substituted or unsubstituted thiazole ring. The invention also relates to said compounds according to formula (I), in particular diastereoisometrically pure or enriched forms thereof, for use in the treatment, in particular in the treatment and / or prevention of age-related cognitive decline. Furthermore, the present invention relates to the use of said compounds according to formula (I) for improving cognitive function, in particular for improving the spatial learning ability of a human individual. Furthermore, the invention relates to the use of said compounds according to formula (I) for the treatment and / or prophylaxis of alcohol addiction, nicotine addiction and / or drug addiction, in particular cocaine and / or methamphetamine addiction.

The invention relates to compositions comprising a synaptic vesicle glycoprotein 2A (SV2A) inhibitor in an extended release and an acetylcholinesterase inhibitor (AChEIs). The invention also relates to using such compositions in treating cognitive impairment associated with central nervous system disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism, compulsive behavior, and substance addiction.

The invention relates to a drug containing a heterocyclic system of a hexatomic ring with nitrogen as a heteroatom, in particular to an application of hirsutine in preparing a drug for preventing and treating opioid substance addiction or amphetamine substance dependence. The drug is composed of the hirsutine and a pharmaceutically acceptable auxiliary material, wherein, the hirsutine content is 5-85%. The drug is oral preparation such as a tablet or a capsule and the like.

The invention provides methods and compositions for treating opioid addiction by identifying patients at high risk of failing opioid agonist replacement therapy before therapy has begun. Related compositions, in the form of kits, systems, and computer-readable media are also provided.

Disclosed are pharmaceutical compositions comprising a benzodiazepine, an alcohol aversive agent, and an abuse aversive agent, and methods of use in preventing alcohol or cocaine abuse.

The invention relates to compositions comprising a synaptic vesicle glycoprotein 2A (SV2A) inhibitor in an extended release and an acetylcholinesterase inhibitor (AChEIs). The invention also relates to using such compositions in treating cognitive impairment associated with central nervous system disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism, compulsive behavior, and substance addiction.

The present invention provides methods for treating a substance addiction-related behavior in a patient with a substance addiction, comprising the step of locally administering a therapeutically effective amount of a botulinum neurotoxin to a location on the patient's body or in the vicinity of the area which comes into contact with a smoking tool or addictive substance, thereby altering, reducing or eliminating sensations associated with behaviors associated with substance addiction. Botulinum neurotoxin may be administered to a dermal, subdermal, mucosal or submucosal location or to a muscle area or in the vicinity of the location to which a smoking tool or addictive substance contacts.

The invention relates to the design and synthesis of novel anabaseine-based compounds, which are useful in treating or preventing a wide variety of conditions, including nervous system diseases or disorders, such as, schizophrenia, Alzheimer's disease, Parkinson's disease, drug dependence, and substance addiction, and compositions, kits, and methods thereof. The invention also provides novel anabaseine-based compounds, compositions, kits, and methods thereof for treating or preventing non-nerve system diseases or disorders (such as, inflammation and cancer) in a subject identified in need thereof. Certain enantiomeric compounds of the invention exhibited enhanced selectivity toward α7 nAChRs relative to alpha4beta2 nAChRs. Other enantiomeric compounds of the invention exhibited enhanced selectivity for alpha4beta2 nAChRs relative to α7 nAChRs.

The invention relates to a novel application of a high-selectivity 5-hydroxytryptamine 5-HT2C receptor agonist WAY163909. A molecular formula of the high-selectivity 5-hydroxytryptamine 5-HT2C receptor agonist WAY163909 is C14H18N2, the molecular weight is 214.30600, and the high-selectivity 5-hydroxytryptamine 5-HT2C receptor agonist WAY163909 is white powder and has good water solubility. The invention discloses the application of the high-selectivity 5-hydroxytryptamine 5-HT2C receptor agonist WAY163909 in preparation of medicines for inhibiting addiction and withdrawl reactions of opioid substances such as morphine, or the application in preparation of the medicines for inhibiting the addiction and withdrawl reactions of morphine substances. According to the novel application disclosed by the invention, the latest researches show that WAY163909 (0.5-1.0mg / kg) can be used for significantly reducing the horizontal movement distance, horizontal movement speed and the withdrawal reactions of mice after morphine-dependent mice are subjected to naloxone precipitation. The novel application disclosed by the invention discovers that WAY163909 can be used for rescuing and treating the addiction and withdrawl reactions produced by the opioid substances such as morphine in clinical treatment and can be used for treating the possible recurrences for the first time.

The present disclosure relates to a chemical compound having the general formula (I):wherein R1 is a phenyl group and R2 is a meta-substituted phenyl group; and RTA is a substituted or unsubstituted thiazole ring. The disclosure also relates to said compound according to formula (I), in particular in its diastereomerically pure or enriched form, for use in therapy, in particular for treating and / or preventing age-related cognitive decline. Further, the disclosure relates to said compound according to formula (I) for use in improving cognitive functions, in particular for use in improving the spatial learning capabilities in human individuals. And, disclosure also relates to said compound according to formula (I) for use in the treatment and / or prevention of alcohol addiction, nicotine addiction and / or drug addiction, in particular cocaine and / or metamphetamine addiction.

The present invention provides for the treatment of disorders related to TLR7 / 8 overexpression or abherrant activation, wherein the disorder is selected from multiple sclerosis, Alzheimer's Disease, myositis, stroke, ischemia, CNS neuropathies, systemic lupus erythematosus, lupus nephritis, Sjogren's syndrome, Guillain-Barr syndrome, alcoholic hepatitis, non-alcoholic steatohepatitis, congenital heart block, autoimmune hepatitis, autoimmune pancreatitis, adult onset Still's disease, drug-induced neurological disorders, and substance addiction, using a compound of Formula (I).

The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.

The invention relates to compositions comprising a synaptic vesicle glycoprotein 2A (SV2A) inhibitor in an extended release and an acetylcholinesterase inhibitor (AChEIs). The invention also relates to using such compositions in treating cognitive impairment associated with central nervous system disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism, compulsive behavior, and substance addiction.